Related Experiment Video
Updated: Jul 15, 2026
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Immunologic approaches to therapy for brain tumors
1Department of Immunology, University of Colorado Health Sciences Center, 4200 E. Ninth Avenue, Denver, CO 80262, USA.
Current Neurology and Neuroscience Reports
|March 20, 2002
Summary
Malignant brain tumors like gliomas are invasive. This review explores clinical trials for adjuvant therapies that directly kill tumor cells or enhance the immune system
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer Biology
Background:
- Malignant brain tumors, particularly gliomas, exhibit invasive growth patterns.
- Surgical debulking removes the primary tumor mass but leaves infiltrating glioma cells.
- Recurrent tumors often arise from these residual single cells or small tumor pockets.
Purpose of the Study:
- To review current clinical trials for adjuvant therapies targeting invasive glioma cells.
- To examine strategies for direct glioma cell lysis.
- To assess approaches enhancing glioma visibility to the endogenous immune system.
Main Methods:
- Review of ongoing clinical trials in brain tumor adjuvant therapy.
- Analysis of therapeutic strategies involving direct cellular contact or proximity effects.
- Evaluation of immunomodulatory approaches for brain tumors.
Main Results:
- Multiple clinical trials are investigating direct tumor cell killing mechanisms.
- Several strategies aim to improve the immune system's recognition and attack of gliomas.
- Adjuvant therapies require effective cell-to-cell contact or proximity for efficacy.
Conclusions:
- Adjuvant treatments are crucial for eradicating residual glioma cells post-surgery.
- Targeting invasive glioma cells requires direct lysis or immune system activation.
- Future therapies may combine direct killing with immune enhancement for better outcomes.
